DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
